| scholarly article | Q13442814 |
| P2093 | author name string | P Romano | |
| A B Gottlieb | |||
| L T Dooley | |||
| D G Baker | |||
| U Chaudhari | |||
| L D Mulcahy | |||
| P2860 | cites work | Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases | Q29547555 |
| The pathogenesis of psoriasis: immunological facts and speculations | Q33542328 | ||
| Cytokines and chemokines in the initiation and regulation of epidermal Langerhans cell mobilization | Q33874509 | ||
| Construction and initial characterization of a mouse-human chimeric anti-TNF antibody | Q34060890 | ||
| Psoriasis. Immunopathology and immunomodulation | Q34436469 | ||
| Severe Psoriasis – Oral Therapy with a New Retinoid | Q34690752 | ||
| The immunology of psoriasis | Q35887607 | ||
| Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells | Q36368842 | ||
| Tumor necrosis factor | Q37241923 | ||
| IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach | Q37378185 | ||
| Treatment of psoriasis | Q40580609 | ||
| Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis | Q40625955 | ||
| Aetiology and pathogenesis of psoriasis | Q41350692 | ||
| Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions | Q41355139 | ||
| Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial | Q43796582 | ||
| The economic impact of psoriasis increases with psoriasis severity. | Q50928286 | ||
| Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. | Q54110885 | ||
| Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis | Q71160284 | ||
| Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions | Q72344499 | ||
| Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis | Q73374703 | ||
| Immunopathogenesis of psoriasis. The road from bench to bedside is a 2-way street | Q73446557 | ||
| Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions | Q73700287 | ||
| Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis | Q74212695 | ||
| Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial | Q74265787 | ||
| P433 | issue | 9271 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1842-7 | |
| P577 | publication date | 2001-06-09 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial | |
| P2283 | uses | randomized experiment | Q1231081 |
| P478 | volume | 357 |
Search more.